Sugi Predict

Sugi Predict / Compounds / SCHEMBL352694

SCHEMBL352694

SCHEMBL352694

CN(C)c1cccc(N(C)C)c1-c1ccccc1P1C(C)(C)CC(=O)CC1(C)C

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ MAPK1 P28482 2/20 0.45
▸ TDP1 Q9NUW8 2/20 0.45
▸ NSD2 O96028 1/20 0.45
▸ EGFR P00533 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ PDK2 Q15119 1/20 0.36
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ PTK2B Q14289 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ USP2 O75604 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.30
▸ PABPC1 P11940 1/20 0.30
▸ GSK3B P49841 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10177359 0.92 ALDH1A1 (0.41) L3MBTL1ALDH1A1MAPTMAPK1TDP1
SCHEMBL351057 0.89 CA1 (0.39) L3MBTL1ALDH1A1MAPTMAPK1TDP1
SCHEMBL351835 0.89 ALDH1A1 (0.37) L3MBTL1ALDH1A1MAPTMAPK1TDP1
SCHEMBL24535424 0.82 TDP2 (0.33) L3MBTL1ALDH1A1MAPTMAPK1NSD2
SCHEMBL18922610 0.80 NSD2 (0.40) L3MBTL1ALDH1A1MAPTMAPK1TDP1
SCHEMBL20862836 0.79 NSD2 (0.38) L3MBTL1ALDH1A1MAPTMAPK1TDP1
SCHEMBL351987 0.78 CA1 (0.42) L3MBTL1ALDH1A1MAPTMAPK1TDP1
SCHEMBL16767936 0.77 NSD2 (0.39) L3MBTL1ALDH1A1MAPTMAPK1TDP1
SCHEMBL350060 0.76 NPC1 (0.35) ALDH1A1LMNAKMT2ARAB9A
SCHEMBL10177360 0.75 BRD4 (0.35) ALDH1A1MAPTLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593226-B1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS ABBVIE IRELAND UNLIMITED CO (IE) 2018-11-14 — — EP claimed
EP-2593439-B1 PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS ABBVIE BAHAMAS LTD (BS) 2016-08-17 — — EP claimed
US-9381508-B2 Phosphine ligands for catalytic reactions ABBVIE INC. (US) 2016-07-05 — — US claimed
US-20150360215-A1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS ABBVIE INC. 2015-12-17 — — US claimed
US-9200021-B2 Phosphine ligands for catalytic reactions ABBVIE INC. (US) 2015-12-01 — — US claimed
US-20150152126-A1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS ABBVIE INC. 2015-06-04 — — US claimed
US-8975443-B2 Phosphine ligands for catalytic reactions ABBVIE INC. (US) 2015-03-10 — — US claimed
US-8895737-B2 Process for preparing antiviral compounds ABBVIE INC. 2014-11-25 — — US claimed
US-8841487-B2 Phosphine ligands for catalytic reactions ABBVIE INC. (US) 2014-09-23 — — US claimed
US-20130217876-A1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS ABBVIE INC. (US) 2013-08-22 — — US claimed
EP-2593226-A1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS Abbvie Inc. (US) 2013-05-22 — — EP claimed
EP-2593439-A2 PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS Abbvie Inc. (US) 2013-05-22 — — EP claimed
US-20120022252-A1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS ABBOTT LABORATORIES (US) 2012-01-26 — — US claimed
US-20120014913-A1 PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2012-01-19 — — US claimed
WO-2012009698-A1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS ABBOTT LABORATORIES (US) 2012-01-19 — — WO claimed
WO-2012009699-A2 PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2012-01-19 — — WO claimed
EP-3461556-A1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS AbbVie Ireland Unlimited Company (IE) 2019-04-03 — — EP disclosed
EP-3415504-A1 PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS AbbVie Ireland Unlimited Company (IE) 2018-12-19 — — EP disclosed
US-20120014913-A1 PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2012-01-19 — — US disclosed
WO-2012009698-A1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS ABBOTT LABORATORIES (US) 2012-01-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217876-A1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS PHOSPHO1, PLCG2, PPIP5K2 L3MBTL1 2677/4885ALDH1A1 4611/4885MAPT 3777/4885
US-20150152126-A1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS PHOSPHO1, PLCG2, PPIP5K2 L3MBTL1 2677/4885ALDH1A1 4611/4885MAPT 3777/4885
US-20150360215-A1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS PHOSPHO1, PLCG2, PPIP5K2 L3MBTL1 2677/4885ALDH1A1 4611/4885MAPT 3777/4885
US-20120014913-A1 PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS HAVCR2, MAVS, RNASE1 L3MBTL1 3782/4885ALDH1A1 2059/4885MAPT 4108/4885
US-20120022252-A1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS PHOSPHO1, PPIP5K2, ITPA L3MBTL1 2695/4885ALDH1A1 4364/4885MAPT 4495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.